TICKERNERD
Menu
VKTXVKTXHealthcare · Biotechnology

VKTX Stock Forecast: Viking Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$30
−1.87% on the day

The 20 Wall Street analysts covering Viking Therapeutics, Inc. hold a median 12-month price target of $95 — +217.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 3 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.8B
Ticker Nerd rank
32 / 100
Median analyst target
$95
Analysts covering
20
Revenue$0.0
Operating income−$132.6M
Net income−$128.0M
Free cash flow−$125.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.8%
1M
−10.6%
YTD
−14.9%
1Y
+7.4%
From 52W high
−28.9%
From 52W low
+13.9%
$26
$42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VKTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Viking Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
73
Value
72
Revisions
53
Momentum
48
Volatility
37
Issuance
35
Quality
28
Size
27
Growth
19

Accruals (73): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VKTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VKTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26VKTXHigh $125Median $95Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts
18 Buy2 Hold0 Sell
Low $38Median $95High $125

The green dot is the last close — the median target sits +217.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
23 Sept 2026Truist SecuritiesMaintainsBuy$83 → $87
11 Aug 2026JP MorganMaintainsOverweight$75 → $65
11 Aug 2026JP MorganMaintainsOverweight—
30 July 2026Canaccord GenuityMaintainsBuy$107 → $114
30 July 2026Canaccord GenuityMaintainsBuy—
28 May 2026Lake StreetInitiatesBuy$89
28 May 2026Lake StreetInitiatesBuy—
1 May 2026BTIGReiteratesBuy—
30 Apr 2026Cantor FitzgeraldMaintainsOverweight—
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
12 Nov 2025Canaccord GenuityMaintainsBuy—
29 Oct 2025Canaccord GenuityInitiatesBuy—
24 Oct 2025JP MorganMaintainsOverweight—
23 Oct 2025Morgan StanleyMaintainsOverweight—
29 Sept 2025HC Wainwright & Co.ReiteratesBuy—
22 Sept 2025BTIGReiteratesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
24 July 2025CitigroupMaintainsNeutral—
24 July 2025Raymond JamesMaintainsStrong Buy—
25 June 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VKTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VKTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Viking Therapeutics, Inc. returned +7.4% against +16.2% for the S&P 500, dividends included.

VKTX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26VKTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VKTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
9
Analysts cutting
7
Fundamentals

Viking Therapeutics, Inc. (VKTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.4×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
8.6×

Cheaper than 11% of US stocks

EV / EBITDA
−7.6×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−88.9%

Higher than 15% of US stocks

Return on assets
−51.9%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Viking Therapeutics, Inc. (VKTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Viking Therapeutics, Inc. has a market value of $3.8B and an enterprise value of $3.0B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$534.8M.

  • Diluted earnings per share, trailing twelve months: $−4.66.

  • Free cash flow in the twelve months to 30 June 2026: −$418.4M.

  • Shares outstanding: 116.7M.

  • Trailing P/E: −9.4×; forward P/E: −6.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Viking Therapeutics, Inc. employs 65 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

VKTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VKTXViking Therapeutics, Inc.$3.8B
32
TNGXTango Therapeutics, Inc.$3.8B
39
XENEXenon Pharmaceuticals, Inc.$3.6B
41
PBLSParabilis Medicines, Inc.$3.6B
0
CELCCelcuity, Inc.$3.5B
28
RLAYRelay Therapeutics, Inc.$4.1B
73
IDYAIDEAYA Biosciences, Inc.$3.5B
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Viking Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VKTX news & analysis

LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies

Zacks Investment Research · 2 Oct 2026neutral

Eli Lilly presented new efficacy data from its Foundayo and EloraTZP studies. Foundayo showed cardiovascular safety and metabolic benefits, while EloraTZP delivered greater weight loss and A1C reduction in a mid-stage study.

Why it matters — A VKTX watcher would care because Eli Lilly's new weight-loss and metabolic drug data could signal heightened competition in the same therapeutic space Viking operates in.

Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?

The Motley Fool · 2 Oct 2026neutral

Viking Therapeutics raised $575 million in a supplementary public offering following positive trial results. The company's shares now trade below its $35 offering price, and the dilution reduces EPS by about 7.2%, with the earnings yield per dollar invested 14.4% lower.

Why it matters — VKTX watchers would care because the capital raise after trial results and subsequent share dilution affect the company's earnings per share and the value offered to investors.

Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts

Zacks Investment Research · 30 Sept 2026positive

Viking Therapeutics, Inc. (VKTX) closed the recent trading session at $32.74, a +2.92% increase from its previous close, rising even as the broader market declined.

Why it matters — A VKTX watcher would care because the stock gained ground despite a weaker market, showing relative strength in the session.

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

The Motley Fool · 30 Sept 2026positive

Viking Therapeutics' stock rose 36% following encouraging results from a maintenance clinical trial of its leading weight-loss drug candidate. The medicine could potentially become a notable player in the weight-loss market based on these results.

Why it matters — The positive trial data suggests Viking's lead candidate may be a significant competitor in the growing weight-loss market, which could drive further investor interest in the company.

FAQ

Frequently asked questions about VKTX stock

What is the VKTX stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Viking Therapeutics, Inc. have a median 12-month price target of $95, with estimates ranging from $38 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VKTX stock a buy right now?

Of the 20 analysts covering Viking Therapeutics, Inc., 18 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viking Therapeutics, Inc. 32 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VKTX?

As at 3 Oct 2026, Viking Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (73 of 100).

Will VKTX stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +217.3% from the last close, and Ticker Nerd's factor model ranks Viking Therapeutics, Inc. 32 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VKTX stock forecast for 2030?

No analyst covering Viking Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VKTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $125 over the next 12 months.

How has VKTX stock performed over the past year?

Viking Therapeutics, Inc. returned +7.4% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Viking Therapeutics, Inc. do?

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders.

What is the latest news on VKTX?

The most recent item we track (Zacks Investment Research, 2 Oct 2026): "LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies". Eli Lilly presented new efficacy data from its Foundayo and EloraTZP studies. Foundayo showed cardiovascular safety and metabolic benefits, while EloraTZP delivered greater weight loss and A1C reduction in a mid-stage study.

Company

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic conditions, along with VK2809, a thyroid hormone receptor beta agonist being evaluated for metabolic liver disease. The company also works on VK0214 for X-linked adrenoleukodystrophy, VK5211 for recovery after hip fracture surgery, VK0612 for metabolic disorders and anemia, and VK3019, an amylin receptor agonist in early study. Based in San Diego, California, Viking Therapeutics is positioned as a research-focused drug developer addressing high-need areas across obesity, liver disease, rare disease, and other endocrine-related conditions.

CEO Dr. Brian Lian Ph.D. · 65 employees · United States · https://www.vikingtherapeutics.com